Acromegaly - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Acromegaly Emerging Therapy and TPP Insights

Thelansis's "Acromegaly Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Acromegaly Overview

Acromegaly is an insidious endocrine disorder characterized by progressive somatic overgrowth driven by chronic growth hormone (GH) hypersecretion-typically from a benign pituitary adenoma-and subsequent elevation of insulin-like growth factor 1 (IGF-1). Because its onset is subtle, definitive diagnosis is notoriously delayed by four to ten years. Left unmanaged, patients develop distinctly enlarged, spade-like extremities, facial bone distortions, and systemic morbidities including hypertrophic cardiomyopathy and secondary diabetes mellitus. Transsphenoidal surgical resection remains the definitive first-line standard to remove the tumor. For persistent or inoperable disease, targeted medical management is required to normalize circulating IGF-1 levels. Crucially, the long-standing monopoly of painful, monthly injected somatostatin receptor ligands (SRLs) has been broken. The medical paradigm now centers on Palsonify (paltusotine), the first FDA-approved once-daily oral nonpeptide SST2 agonist. Backed by long-term data demonstrating robust, sustained biochemical control and reduced standard systemic symptoms, oral paltusotine bypasses conventional injection-site complications. For severe, non-responsive phenotypes, it can be combined with oral cabergoline or escalated to the GH receptor antagonist pegvisomant to prevent systemic structural degradation.

Key Highlights

• In Germany, prevalent acromegaly cases are projected to increase from approximately 6,726 in 2025 to 7,022 by 2035.
• Acromegaly is a rare endocrine disorder caused primarily by growth hormone-secreting pituitary adenomas.
• Delayed diagnosis remains a major challenge due to the gradual onset of symptoms.
• Long-term complications include cardiovascular disease, metabolic disorders, and reduced quality of life.
• Advances in medical therapies and disease monitoring are improving disease control rates.

Market Overview

• The France acromegaly market is projected to grow from approximately $420 MN to $630 MN by 2035.
• Market growth is supported by:
• Increasing utilization of somatostatin analogs and targeted therapies
• Improved long-term management of chronic disease
• Market value growth is driven by prolonged treatment duration and premium biologic therapies.
• Future growth will depend on next-generation endocrine therapies and personalized treatment strategies.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Alexion Pharmaceuticals, Inc.
• Crinetics Pharmaceuticals Inc.
• Camurus AB
• Debiopharm International SA
• Marea Therapeutics
• Immunwork, Inc.